Drugs for rare diseases: Common list of drugs

The common list of new drugs ensures that the National Strategy for Drugs for Rare Diseases delivers the most possible benefits to all patients with rare diseases.

We will publish the names of drugs on the common list as the pan-Canadian Pharmaceutical Alliance concludes its price negotiations. We will also add information on which drugs each province and territory has elected to make available to their residents under bilateral agreements.

Common list of drugs

Currently, the publicly announced drugs on the common list are:

• Poteligeo (Mycosis fungoides or Sézary syndrome)
• Oxlumo (Primary hyperoxaluria type 1)
• Epkinly (Relapsed or refractory diffuse large B-cell lymphoma)
• Welireg (Von Hippel-Lindau disease)
• Yescarta (Follicular lymphoma; 2^nd line treatment of diffuse large B-cell lymphoma or high-grade large B-cell lymphoma)
• Koselugo (Neurofibromatosis type 1)
• Sohonos (Fibrodysplasia ossificans progressiva (FOP))
• Imcivree (Bardet-Biedl syndrome)
• Evkeeza (Homozygous familial hypercholesterolemia)
• Hemgenix (Hemophilia B (congenital Factor IX deficiency))
• Breyanzi (2^nd line treatment of diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, or high-grade large B-cell lymphoma, in patients who are also candidates of autologous hematopoietic stem cell transplant)
• Enhertu (2^nd line treatment for HER2-positive gastric or gastroesophageal junction cancer)
• Columvi (3^rd line treatment for follicular lymphoma, diffuse large B-cell lymphoma, or primary mediastinal large B-cell lymphoma)
• Winrevair (Pulmonary arterial hypertension)
• Livmarli (Cholestatic pruritus in patients with Alagille syndrome)

Note: The targeted disease state is provided for information. However, each drug has a detailed and specific Health Canada approved indication, which can be found in the Drug Product Database.

Elected drugs on the common list, by province or territory

Alberta

• Poteligeo (Mycosis fungoides or Sézary syndrome)
• Oxlumo (Primary hyperoxaluria type 1)
• Epkinly (Relapsed or refractory diffuse large B-cell lymphoma)
• Welireg (Von Hippel-Lindau disease)
• Koselugo (Neurofibromatosis type 1)
• Yescarta (Follicular lymphoma; 2^nd line treatment of diffuse large B-cell lymphoma or high-grade large B-cell lymphoma)
• Sohonos (Fibrodysplasia ossificans progressiva (FOP))
• Imcivree (Bardet-Biedl syndrome)
• Evkeeza (Hypercholestérolémie familiale homozygote)
• Enhertu (2^nd line treatment for HER2-positive gastric or gastroesophageal junction cancer)
• Columvi (3^rd line treatment for follicular lymphoma, diffuse large B-cell lymphoma, or primary mediastinal large B-cell lymphoma)
• Livmarli (Cholestatic pruritus in patients with Alagille syndrome)

British Columbia

• Poteligeo (Mycosis fungoides or Sézary syndrome)
• Oxlumo (Primary hyperoxaluria type 1)
• Epkinly (Relapsed or refractory diffuse large B-cell lymphoma)
• Welireg (Von Hippel-Lindau disease)
• Yescarta (Follicular lymphoma; 2^nd line treatment of diffuse large B-cell lymphoma or high-grade large B-cell lymphoma)
• Koselugo (Neurofibromatosis type 1)
• Sohonos (Fibrodysplasia ossificans progressiva (FOP))
• Imcivree (Bardet-Biedl syndrome)
• Evkeeza (Homozygous familial hypercholesterolemia)
• Hemgenix (Hemophilia B (congenital Factor IX deficiency))
• Breyanzi (2^nd line treatment of diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, or high-grade large B-cell lymphoma, in patients who are also candidates of autologous hematopoietic stem cell transplant)
• Enhertu (2^nd line treatment for HER2-positive gastric or gastroesophageal junction cancer)
• Columvi (3^rd line treatment for follicular lymphoma, diffuse large B-cell lymphoma, or primary mediastinal large B-cell lymphoma)
• Winrevair (Pulmonary arterial hypertension)
• Livmarli (Cholestatic pruritus in patients with Alagille syndrome)

Manitoba

• Poteligeo (Mycosis fungoides or Sézary syndrome)
• Oxlumo (Primary hyperoxaluria type 1)
• Epkinly (Relapsed or refractory diffuse large B-cell lymphoma)
• Welireg (Von Hippel-Lindau disease)
• Yescarta (Follicular lymphoma; 2^nd line treatment of diffuse large B-cell lymphoma or high-grade large B-cell lymphoma)
• Koselugo (Neurofibromatosis type 1)
• Sohonos (Fibrodysplasia ossificans progressiva (FOP))
• Enhertu (2^nd line treatment for HER2-positive gastric or gastroesophageal junction cancer)
• Columvi (3^rd line treatment for follicular lymphoma, diffuse large B-cell lymphoma, or primary mediastinal large B-cell lymphoma)
• Winrevair (Pulmonary arterial hypertension)

New Brunswick

• Poteligeo (Mycosis fungoides or Sézary syndrome)
• Oxlumo (Primary hyperoxaluria type 1)
• Epkinly (Relapsed or refractory diffuse large B-cell lymphoma)
• Welireg (Von Hippel-Lindau disease)
• Yescarta (Follicular lymphoma; 2^nd line treatment of diffuse large B-cell lymphoma or high-grade large B-cell lymphoma)
• Koselugo (Neurofibromatosis type 1)
• Breyanzi (2^nd line treatment of diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, or high-grade large B-cell lymphoma, in patients who are also candidates of autologous hematopoietic stem cell transplant)
• Enhertu (2^nd line treatment for HER2-positive gastric or gastroesophageal junction cancer)
• Columvi (3^rd line treatment for follicular lymphoma, diffuse large B-cell lymphoma, or primary mediastinal large B-cell lymphoma)

Newfoundland and Labrador

• Poteligeo (Mycosis fungoides or Sézary syndrome)
• Oxlumo (Primary hyperoxaluria type 1)
• Epkinly (Relapsed or refractory diffuse large B-cell lymphoma)
• Welireg (Von Hippel-Lindau disease)
• Yescarta (Follicular lymphoma; 2^nd line treatment of diffuse large B-cell lymphoma or high-grade large B-cell lymphoma)
• Koselugo (Neurofibromatosis type 1)
• Sohonos (Fibrodysplasia ossificans progressiva (FOP))
• Imcivree (Bardet-Biedl syndrome)
• Evkeeza (Homozygous familial hypercholesterolemia)
• Enhertu (2^nd line treatment for HER2-positive gastric or gastroesophageal junction cancer)
• Columvi (3^rd line treatment for follicular lymphoma, diffuse large B-cell lymphoma, or primary mediastinal large B-cell lymphoma)

Northwest Territories

• Poteligeo (Mycosis fungoides or Sézary syndrome)
• Epkinly (Relapsed or refractory diffuse large B-cell lymphoma)
• Yescarta (Follicular lymphoma; 2^nd line treatment of diffuse large B-cell lymphoma or high-grade large B-cell lymphoma)
• Breyanzi (2^nd line treatment of diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, or high-grade large B-cell lymphoma, in patients who are also candidates of autologous hematopoietic stem cell transplant)
• Enhertu (2^nd line treatment for HER2-positive gastric or gastroesophageal junction cancer)
• Columvi (3^rd line treatment for follicular lymphoma, diffuse large B-cell lymphoma, or primary mediastinal large B-cell lymphoma)

Nova Scotia

• Poteligeo (Mycosis fungoides or Sézary syndrome)
• Oxlumo (Primary hyperoxaluria type 1)
• Epkinly (Relapsed or refractory diffuse large B-cell lymphoma)
• Welireg (Von Hippel-Lindau disease)
• Yescarta (Follicular lymphoma; 2^nd line treatment of diffuse large B-cell lymphoma or high-grade large B-cell lymphoma)
• Koselugo (Neurofibromatosis type 1)
• Sohonos (Fibrodysplasie ossifiante progressive (FOP))
• Imcivree (Bardet-Biedl syndrome)
• Evkeeza (Hypercholestérolémie familiale homozygote)
• Enhertu (2^nd line treatment for HER2-positive gastric or gastroesophageal junction cancer)
• Columvi (3^rd line treatment for follicular lymphoma, diffuse large B-cell lymphoma, or primary mediastinal large B-cell lymphoma)
• Winrevair (Pulmonary arterial hypertension)
• Livmarli (Cholestatic pruritus in patients with Alagille syndrome)

Nunavut

• Poteligeo (Mycosis fungoides or Sézary syndrome)
• Epkinly (Relapsed or refractory diffuse large B-cell lymphoma)
• Welireg (Von Hippel-Lindau disease)
• Yescarta (Follicular lymphoma; 2^nd line treatment of diffuse large B-cell lymphoma or high-grade large B-cell lymphoma)
• Breyanzi (2^nd line treatment of diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, or high-grade large B-cell lymphoma, in patients who are also candidates of autologous hematopoietic stem cell transplant)
• Enhertu (2^nd line treatment for HER2-positive gastric or gastroesophageal junction cancer)
• Columvi (3^rd line treatment for follicular lymphoma, diffuse large B-cell lymphoma, or primary mediastinal large B-cell lymphoma)
• Winrevair (Pulmonary arterial hypertension)

Ontario

• Poteligeo (Mycosis fungoides or Sézary syndrome)
• Oxlumo (Primary hyperoxaluria type 1)
• Epkinly (Relapsed or refractory diffuse large B-cell lymphoma)
• Welireg (Von Hippel-Lindau disease)
• Yescarta (Follicular lymphoma; 2^nd line treatment of diffuse large B-cell lymphoma or high-grade large B-cell lymphoma)
• Koselugo (Neurofibromatosis type 1)
• Sohonos (Fibrodysplasia ossificans progressiva (FOP))
• Imcivree (Bardet-Biedl syndrome)
• Evkeeza (Homozygous familial hypercholesterolemia)
• Hemgenix (Hemophilia B (congenital Factor IX deficiency))
• Breyanzi (2^nd line treatment of diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, or high-grade large B-cell lymphoma, in patients who are also candidates of autologous hematopoietic stem cell transplant)
• Enhertu (2^nd line treatment for HER2-positive gastric or gastroesophageal junction cancer)
• Columvi (3^rd line treatment for follicular lymphoma, diffuse large B-cell lymphoma, or primary mediastinal large B-cell lymphoma)
• Winrevair (Pulmonary arterial hypertension)
• Livmarli (Cholestatic pruritus in patients with Alagille syndrome)

Prince Edward Island

• Poteligeo (Mycosis fungoides or Sézary syndrome)
• Epkinly (Relapsed or refractory diffuse large B-cell lymphoma)
• Koselugo (Neurofibromatosis type 1)

Saskatchewan

• Poteligeo (Mycosis fungoides or Sézary syndrome)
• Oxlumo (Primary hyperoxaluria type 1)
• Epkinly (Relapsed or refractory diffuse large B-cell lymphoma)
• Welireg (Von Hippel-Lindau disease)
• Yescarta (Follicular lymphoma; 2^nd line treatment of diffuse large B-cell lymphoma or high-grade large B-cell lymphoma)
• Koselugo (Neurofibromatosis type 1)
• Sohonos (Fibrodysplasia ossificans progressiva (FOP))
• Imcivree (Bardet-Biedl syndrome)
• Evkeeza (Homozygous familial hypercholesterolemia)
• Enhertu (2^nd line treatment for HER2-positive gastric or gastroesophageal junction cancer)
• Columvi (3rd line treatment for follicular lymphoma, diffuse large B-cell lymphoma, or primary mediastinal large B-cell lymphoma)
• Winrevair (Pulmonary arterial hypertension)
• Livmarli (Cholestatic pruritus in patients with Alagille syndrome)

Yukon

• Yescarta (Follicular lymphoma; 2^nd line treatment of diffuse large B-cell lymphoma or high-grade large B-cell lymphoma)